Paromomycinsulfate
PAROMOMYCIN SULPHATE · sulf · humatin · NEOMYCIN E · PAROMOMYCIN SULFATE SALT · Neomycin Sulfate EP Impurity E · O - 2, 6 - Diamino - 2, 6 - dideoxy - b - L - idopyranosyl - (1,3) - O - b - D - ribofuranosyl - (1,5) - O - [2 - amino - 2 - deoxy - a - D - glucopyranosyl - (1,4) ] - 2 - deoxy - streptamine sulfate · fi5853
Identifikatoren & physikalische Daten
| CAS No. | 1263-89-4 |
|---|---|
| Summenformel | C23H47N5O18S |
| Durchschnittliche Molmasse | 713,7 g/mol |
| Monoisotopische Masse | 713,26368084 g/mol |
| SMILES | NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O.O=S(=O)(O)O |
| InChIKey | LJRDOKAZOAKLDU-UDXJMMFXSA-N |
| PubChem CID | 441375 |
| ChEMBL | CHEMBL2206196 |
| ChEBI | CHEBI:7935 |
| EC No. | 215-031-7 |
| DTXSID | DTXSID601335979 |
| Lokaler Name | Paromomycinsulfate |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 430 |
|---|---|
| H-Brücken-Donoren | 15 |
| H-Brücken-Akzeptoren | 23 |
| Frei drehbare Bindungen | 9 |
| Schwere Atome | 47 |
| Formalladung | 0 |
| Komplexität | 952 |
| Schmelzpunkt | 145 °C (decomp) |
| Lagerbedingungen | Keep in dark place,Inert atmosphere,Room temperature |
| Löslichkeit | H2O: 50 mg/mL store stock solution at 2-8°C. Stable at 37°C for 5 days.Soluble in water |
| Aggregatzustand | powder |
| Farbe | White to Off-White |
| Merck | 14,7041 |
| BRN | 5715182 |
| Stabilität | Hygroscopic |
| InChIKey | LJRDOKAZOAKLDU-UDXJMMFXSA-N |
| CAS Datenbank | 1263-89-4 |
| EPA chemische Informationen | Paromomycin sulfate (1263-89-4) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 93% (53 of 57) of all reports.Not ClassifiedReported as not meeting GHS hazard criteria by 53 of 57 companies (only 7% companies provided GHS information). For more detailed information, please visit ECHA C&L website.Aggregated GHS information provided per 57 reports by companies from 5 notifications to the ECHA C&L Inventory.Reported as not meeting GHS hazard criteria per 53 of 57 reports by companies.There are 4 notifications provided by 4 of 57 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Regulatorische Informationen | Regulation (EC) No 1831/2003 (amended) |
| Hazard Classes and Categories | Not Classified |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Paromomycin sulfatevNo-DILI-concernNo matchDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during LactationNo information is available on the clinical use of paromomycin during breastfeeding. Because paromomycin is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants.◉ Effects in Breastfed InfantsRelevant published information was not found as of the revision date.◉ Effects on Lactation and Breastmilk |
| Wassergefährdungsklasse (WGK) | 2 |
| Zollcode | 2941901010 |
| RTECS-Nr. | WK2320000 |
| R-Sätze (R) | 23/24/25-36/38-39/23/24/25-61-36/37/38 |
Anwendungen & Verwendung
Beschreibung
Paromomycin was found in the culture broth of Streptomyces rimosus forma paromomycinus by Parke Davis & Co. in 1959. In the same year it was found in the culture broth of S. Crestomyceticus by Farmitalia and named amminosidin. Paromomycin is related structurally to neomycin, but it has a hydroxyl group at the 6 position, whereas neomycin has an amino group. Its antibacterial activity is weaker than that of neomycin, but its toxicity is much less. Paromomycin is used by intramuscular injection for therapy of respiratory, urinary, and surgical infections and by oral administration to treat dysentery and salmonellosis.
Verwenden
PAROMOMYCIN SULFATE is an aminogycoside antibiotic designed to fight intestinal infections such as cryptosporidiosis, amoebiasis, and leishmaniasis. Its antiprotozoal activity makes it an effecive histomonostatic feed addit ive in turkey poults experimentally infected with Histomonas meleagridis.